$42.59
-1.89-4.25%
At close: -
$42.59
0.000.00%
After Hours: 4:03 PM EDT
Ultragenyx Pharmaceutical reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Ultragenyx Pharmaceutical using advanced sorting and filters.
Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-13 | $-1.39 | $-1.27 | -9.45 % |
Q3 | 2024-11-05 | $-1.40 | $-1.45 | 3.45 % |
Q2 | 2024-08-01 | $-1.52 | $-1.72 | 11.6 % |
Q1 | 2024-05-02 | $-2.03 | $-1.76 | -15.3 % |
Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-13 | $164.88M | $158.71M | 3.89 % |
Q3 | 2024-11-05 | $139.49M | $135.79M | 2.73 % |
Q2 | 2024-08-01 | $147.03M | $123.18M | 19.4 % |
Q1 | 2024-05-02 | $108.83M | $116.17M | -6.32 % |
Ultragenyx Pharmaceutical (RARE) is scheduled to report earnings on May 1, 2025. The last reported earnings were for reported on February 13, 2025 for Q4.
The Actual EPS was $-1.39, which missed the estimate of $-1.27.
The Actual Revenue was $164.9M, which beat the estimate of $158.7M.
Browse earnings estimates, EPS, and revenue on all stocks.